Neuren Media and Analyst Coverage, page-654

Hi RoyalWulff, thanks for your thoughts.

Personally, I think you should share your numbers that are on the high side. Especially if you have worked your DCF numbers over such a large time period. It woukd be somewhat refined.

It is always helpful to see where Neu is potentially heading, if success is multi headed.

I get a valuation of just under $40 per share on a high 30’s PE at 3000 patients just for US Daybue.

Rolling in the other indications and ROW is important IMO.

Many have come up with “crazy” numbers. And only mention them in whispers for perceptions of being ridiculous.

But, they are not. People have come up with those numbers based on information at hand. Yes, future valuations. With varying success rates and market penetration.

It is not long ago some holders were happy with a couple of bucks above $10.

This is a quickly changing beast in terms of SP targets now.

I would happily hear peoples high end target share prices and the reasoning/formula behind those valuations.

ATB TL